公开(公告)号：US11324818B2

公开(公告)日：2022-05-10

申请号：US16334683

申请日：2017-09-21

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Abdolamir Landi ,  Michael Logan ,  John L. Law ,  Darren Hockman ,  Chao Chen

IPC分类号： A61K39/29 ,  A61K39/12 ,  A61K39/00

摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.

公开(公告)号：US20220105175A1

公开(公告)日：2022-04-07

申请号：US17511177

申请日：2021-10-26

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Abdolamir Landi ,  Michael Logan ,  John L. Law ,  Darren Hockman ,  Chao Chen

IPC分类号： A61K39/29 ,  A61K39/12

摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.

公开(公告)号：US10881727B2

公开(公告)日：2021-01-05

申请号：US16374403

申请日：2019-04-03

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC分类号： A61K39/00 ,  C07K16/28 ,  A61K39/21 ,  A61K48/00 ,  C12N15/86 ,  A61K39/29 ,  A61K39/12 ,  A61P37/04 ,  A61P31/14 ,  A61P31/04 ,  A61K39/295 ,  C12N15/861

摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US20180169219A1

公开(公告)日：2018-06-21

申请号：US15574427

申请日：2016-07-06

申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

发明人： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC分类号： A61K39/29 ,  A61K39/295 ,  C12N15/861 ,  A61P31/14 ,  A61P31/04 ,  A61P37/04

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K39/295 ,  A61K2039/55544 ,  A61P31/04 ,  A61P31/14 ,  A61P37/04 ,  C07K2319/00 ,  C12N15/861 ,  C12N2770/24234

摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US11186615B2

公开(公告)日：2021-11-30

申请号：US15763370

申请日：2016-10-07

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Chao Chen ,  Michael Logan

IPC分类号： C07K14/005 ,  C12N15/62 ,  C12P21/02 ,  C07K1/22 ,  C07K19/00 ,  A61K39/12 ,  A61P31/14 ,  A61K39/29 ,  C12N7/00 ,  A61K39/00

摘要： The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.

公开(公告)号：US20210170018A1

公开(公告)日：2021-06-10

申请号：US17122627

申请日：2020-12-15

申请人： The Governors of the University of Alberta ,  Helmholtz Center for Infection Research

发明人： Michael Houghton ,  Abdolamir Landi ,  Carlos A. Guzman ,  Thomas Ebensen ,  Darren Hockman ,  John L. Law ,  Michael Logan

IPC分类号： A61K39/29 ,  C07K14/18 ,  C07K14/33 ,  C12N15/86 ,  C01F11/02 ,  C07D323/00 ,  C07K14/34 ,  A61K39/39 ,  A61P31/14 ,  A61K39/12 ,  A61P37/04 ,  C07K14/28 ,  C07K14/005 ,  A61K39/00

摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

公开(公告)号：US20210145963A9

公开(公告)日：2021-05-20

申请号：US14783699

申请日：2014-05-15

申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

发明人： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC分类号： A61K39/29

摘要： The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

公开(公告)号：US20190224308A1

公开(公告)日：2019-07-25

申请号：US16374403

申请日：2019-04-03

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC分类号： A61K39/29 ,  C12N15/861 ,  A61P31/14 ,  A61P37/04 ,  A61K39/12 ,  A61K39/295 ,  A61P31/04

摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US20160067332A1

公开(公告)日：2016-03-10

申请号：US14783699

申请日：2014-05-05

申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

发明人： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC分类号： A61K39/29

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/70 ,  C12N2770/24234

摘要： The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

摘要翻译： 本公开提供包含来自两种或更多种不同HCV基因型的HCV E1，E2或E1 / E2多肽的免疫原性组合物。 本公开提供包含来自两种或更多种不同HCV基因型的HCV E2或E1 / E2多肽的免疫原性组合物。 免疫原性组合物可用于进行诱导对HCV的免疫应答的方法。 本公开进一步提供刺激个体对HCV的免疫应答的方法。

公开(公告)号：US20240316186A1

公开(公告)日：2024-09-26

申请号：US18520057

申请日：2023-11-27

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC分类号： A61K39/29 ,  A61K39/12

CPC分类号： A61K39/29 ,  A61K39/12 ,  C12N2770/24234

摘要： The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.